Holen Sie sich die Stockscreener-App
3.93
10.08%
0.36
Handel nachbörslich:
4.02
0.09
+2.29%
Schlusskurs vom Vortag:
$3.57
Offen:
$3.56
24-Stunden-Volumen:
10.61M
Relative Volume:
2.88
Marktkapitalisierung:
$648.11M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-196.50
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
+16.96%
1M Leistung:
+19.09%
6M Leistung:
+390.02%
1J Leistung:
+274.29%
1-Tages-Spanne:
$3.50
$4.1599
1-Wochen-Bereich:
$3.22
$4.1599
52-Wochen-Spanne:
$0.40
$4.1599
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.93 | 588.74M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockGlobal Markets & Reliable Intraday Trade Plans - newser.com
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow Jones2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Visual analytics tools that track CytomX Therapeutics Inc. performanceJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy call2025 Trading Recap & Fast Gaining Stock Strategy Reports - newser.com
How to integrate CytomX Therapeutics Inc. into portfolio analysis toolsJuly 2025 Review & Weekly Watchlist for Consistent Profits - newser.com
Will CytomX Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
What analyst consensus implies for CytomX Therapeutics Inc. (6C1) stockJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Is CytomX Therapeutics Inc. (6C1) stock a buy on weakness2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Why retail traders accumulate CytomX Therapeutics Inc. (6C1) stockAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Using data filters to optimize entry into CytomX Therapeutics Inc.Market Trend Report & Reliable Intraday Trade Plans - newser.com
How CytomX Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
What dividend safety rating applies to CytomX Therapeutics Inc. (6C1) stockBond Market & AI Forecasted Entry and Exit Points - newser.com
Published on: 2025-11-02 12:38:04 - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly data2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stockJuly 2025 Intraday Action & Daily Volume Surge Signals - newser.com
Using Ichimoku Cloud for CytomX Therapeutics Inc. technicalsQuarterly Portfolio Report & Long-Term Capital Growth Strategies - newser.com
How CytomX Therapeutics Inc. stock reacts to oil pricesJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Why analysts maintain buy rating on CytomX Therapeutics Inc. (6C1) stockShort Setup & Real-Time Volume Triggers - newser.com
What drives CytomX Therapeutics Inc 6C1 stock priceMarket Sentiment Report & Trusted Financial Advisors at No Cost - earlytimes.in
Is CytomX Therapeutics Inc. (6C1) stock considered safe havenTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Building trade automation scripts for CytomX Therapeutics Inc.2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Can CytomX Therapeutics Inc. stock reach $100 price targetJuly 2025 Update & AI Forecast Swing Trade Picks - newser.com
How CytomX Therapeutics Inc. stock compares to market leadersJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT - MSN
CytomX Therapeutics, Inc. to Report Third Quarter Financial Results on November 6, 2025 - Quiver Quantitative
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Published on: 2025-10-30 05:08:21 - newser.com
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):